Market Overview

Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Share:
Related IDXX
Stocks Hitting 52-Week Highs
12 Contrarian Plays For The Bears
Unleashed: A Wave Of Pet-Friendly Services & Innovations (Investor's Business Daily)
Related NEOG
Neogen Announces Richard Crowder's Resignation As Director
Earnings Scheduled For March 23, 2016

Below are the top diagnostic substances stocks on the NASDAQ in terms of revenue estimate for the current year.

Analysts expect IDEXX Laboratories (NASDAQ: IDXX) to post revenue of $1.30 billion for the year ending December, 2012. IDEXX had $221.44 million in total cash for the latest quarter.

Neogen (NASDAQ: NEOG) is likely to post revenue of $205.21 million in the year ending May, 2013. Neogen's trailing-twelve-month operating margin is 19.11%.

Meridian Bioscience (NASDAQ: VIVO) is expected to report revenue of $189.80 million for the year ending September, 2013. Meridian Bioscience's trailing-twelve-month ROE is 23.73%.

Abaxis (NASDAQ: ABAX) may report revenue of $182.77 million in the year ending March, 2013. Abaxis' PEG ratio is 3.40.

Posted-In: Diagnostic Substances Industry Highest Revenue Estimates NASDAQ StocksTrading Ideas

 

Related Articles (ABAX + IDXX)

View Comments and Join the Discussion!